Share this post on:

product name Tranylcypromine HCl


Description: Tranylcypromine HCl, also known as 2-PCPA, is a nonselective and irreversible monoamine oxidase inhibitor, which inhibits CYP2A6 with Ki of 0.08 μM and 0.2 μM in cDNA-expressing microsomes and Human Liver Microsomes, respectively. Tranylcypromine is used as an antidepressant and anxiolytic agent in the clinical treatment of mood and anxiety disorders, respectively.         

References: Drug Metab Dispos. 2001 Jun;29(6):897-902; Environ Health Perspect. 2004 Aug;112(11):1159-64.



Molecular Weight (MW)

169.65
Formula

C9H12ClN
CAS No.

1986-47-6
Storage

-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)

DMSO: 33 mg/mL (194.5 mM)
Water
Ethanol: 33 mg/mL (194.5 mM)
Solubility (In vivo)

 
Synonyms

SKF-385 HCl

other peoduct :

In Vitro

In vitro activity: R-(+)-Tranylcypromine, (±)-Tranylcypromine, and S-(−)-Tranylcypromine competitively inhibits CYP2A6-mediated metabolism of nicotine with apparent Ki values of 0.05 μM, 0.08 μM, and 2.0 μM, respectively, in human liver microsomes. Tranylcypromine (500 μg/mL) severely inhibits bradykinin-stimulated arachidonic acid release in calf aortic endothelial cells. Tranylcypromine inhibits CYP2A6 and CYP2E1 activity with IC50 of 0.42 μM and 3 μM, respectively, in human liver microsomes. Tranylcypromine induces type II and cyclopropylbenzene type I difference spectrum in human liver microsomes.


Kinase Assay:


Cell Assay

In Vivo Tranylcypromine injection leads to a large, slow increase in motor activity at 5 mg/kg and 10 mg/kg compared with the saline control in male rats, although 2 mg/kg Tranylcypromine does not induce an increase. Tranylcypromine (10 mg/kg) also causes significant decreases in the number of rearing behaviors in male rats.
Animal model  
Formulation & Dosage  
References Drug Metab Dispos. 2001 Jun;29(6):897-902; Environ Health Perspect. 2004 Aug;112(11):1159-64.

ALW-II-41-29

Share this post on:

Author: Sodium channel